Indaptus Therapeutics, Inc. (INDP) stock
Close on Nov 11, 2026Market cap $427.71MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $427.71M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 37.61
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$15.42M
- EPS, diluted
- -$7.74
- Book value per share
- $0.10
- Diluted shares
- 116M
Trading
- Next earnings
- Nov 11, 2026 (estimated, before the open)
- Previous close
- $2.90
- Open
- $3.05
- Day's range
- $3.03 – $3.29
- Volume
- 264,984
- Average volume (20 days)
- 319,321
- Beta (5 years)
- 1.07
- 52-week range
- $0.92 – $5.96
- RSI (14 days)
- 53.5
- Volatility (1 year)
- 205.3%
- Relative volume
- 0.39×
- WACC
- 10.2%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | INDP | S&P 500 | Difference | INDP per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +27.9% | -2.4% | +30.3 pts | ||
| 3 months | +169.7% | -1.2% | +170.9 pts | ||
| Year to date | +10.3% | +12.3% | −2.0 pts | ||
| 1 year | +18.0% | +12.4% | +5.6 pts | ||
| 3 years | -95.1% | +78.8% | −173.9 pts | -63.4% | +21.4% |
| 5 years | -98.4% | +75.2% | −173.6 pts | -56.5% | +11.9% |
| 10 years | -100.0% | +311.1% | −411.1 pts | -55.6% | +15.2% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Indaptus Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- News
- Results
- Update
About Indaptus Therapeutics
Pharmaceutical Preparations
Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company that creates systemically administered immunotherapies to treat cancer and viral infections. The company develops technologies utilizing attenuated and killed, non-pathogenic Gram-negative bacteria to stimulate innate and adaptive immune defenses through intravenous administration. Its primary clinical candidate is Decoy20, an investigational agent evaluated for individuals with advanced solid tumors who have exhausted standard approved therapies. The company focuses on developing treatments intended for oncology patients and healthcare professionals addressing complex malignancies.
Company profile, executives and historyIndaptus Therapeutics stock: common questions
What is Indaptus Therapeutics's stock price?
INDP closed at $3.21 on Nov 11, 2026, up 10.69% on the day. Over the past 52 weeks it traded between $0.92 and $5.96.
What is Indaptus Therapeutics's market cap?
Indaptus Therapeutics was worth $427.71M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is INDP's P/E ratio?
Indaptus Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$7.74), so it has no meaningful P/E ratio.
Does Indaptus Therapeutics pay a dividend?
No. Indaptus Therapeutics has not paid a cash dividend over the last twelve months.
When does Indaptus Therapeutics report earnings next?
Indaptus Therapeutics is expected to report Q3 FY2026 results on Nov 11, 2026, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has INDP stock performed over the past year?
Including dividends, INDP returned +18.0% over the past year, against +12.4% for the S&P 500.
Who are Indaptus Therapeutics's competitors?
Companies most similar to Indaptus Therapeutics by business, industry and size include IMNN, DCOY, APVO, OSTX, PPBT.
See a number that looks wrong?